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AbstrACt 
Introduction Healthcare-associated or nosocomial 
infection (HAI) is distressing to patients and costly 
for the National Health Service (NHS). With increasing 
pressure to demonstrate cost-effectiveness of 
interventions to control HAI and notwithstanding the 
risk from antimicrobial-resistant infections, there is 
a need to understand the incidence rates of HAI and 
costs incurred by the health system and for patients 
themselves.
Methods and analysis The Evaluation of Cost of 
Nosocomial Infection study (ECONI) is an observational 
incidence survey with record linkage and a nested case-
control study that will include postdischarge longitudinal 
follow-up and qualitative interviews. ECONI will be 
conducted in one large teaching hospital and one district 
general hospital in NHS Scotland. The case mix of these 
hospitals reflects the majority of overnight admissions 
within Scotland. An incidence survey will record all 
HAI cases using standard case definitions. Subsequent 
linkage to routine data sets will provide information 
on an admission cohort which will be grouped into 
HAI and non-HAI cases. The case-control study will 
recruit eligible patients who develop HAI and twice that 
number without HAI as controls. Patients will be asked 
to complete five questionnaires: the first during their 
stay, and four others during the year following discharge 
from their recruitment admission (1, 3, 6 and 12 
months). Multiple data collection methods will include 
clinical case note review; patient-reported outcome; 
linkage to electronic health records and qualitative 
interviews. Outcomes collected encompass infection 
types; morbidity and mortality; length of stay; quality 
of life; healthcare utilisation; repeat admissions and 
postdischarge prescribing.
Ethics and dissemination The study has received 
a favourable ethical opinion from the Scotland A 
Research Ethics Committee (reference 16/SS/0199). All 
publications arising from this study will be published 
in open-access peer-reviewed journal. Lay-person 
summaries will be published on the ECONI website.
trial registration number NCT03253640; Pre-results.
IntroduCtIon
Healthcare-associated or nosocomial infec-
tions (HAIs) are infections acquired as a 
result of an episode of healthcare. HAIs are 
distressing for patients, increase their length 
of stay (LOS) and incur additional costs 
to both patient and the healthcare system. 
WHO reports acquisition of infection while 
receiving healthcare as the most frequently 
occurring adverse events.1 HAI affects all 
healthcare systems from the most advanced 
to the lowest resourced. While high-income 
countries have surveillance systems which 
describe the prevalence and incidence 
of selected HAIs, the burden in terms of 
numbers of cases and the attributable impact 
on cost of treatment, patients’ quality of life 
and impact on society is not well described. 
strengths and limitations of this study
 ► This study will describe the whole hospital incidence 
of all healthcare-associated or nosocomial infection 
(HAI) types using internationally comparable case 
definitions including causative organisms and anti-
biotic susceptibilities within two hospitals.
 ► Postdischarge information on the outcome quality of 
life is rarely available; this will be achieved by follow-
ing up patients after discharge with questionnaires.
 ► Routine health record linkage in Scotland allows post 
discharge outcome data which otherwise would re-
quire review of general practitioner's case notes for 
all patients recruited to the case-control study.
 ► Infections without laboratory-confirmed HAI may be 
under-represented.
 ► Some patients may be too unwell to participate in 
the case-control study and may not wish to partici-
pate in the case-control study inevitably, some pa-
tients will be lost to follow-up.
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Antimicrobial resistance (AMR) is an increasing concern 
worldwide and HAI surveillance including AMR is being 
implemented worldwide.2–4 Studies which assess the 
impact of HAI tend to focus on patient morbidity and 
mortality in the hospital, specifically the additional LOS 
in acute care. With average LOS currently decreasing and 
patients with increasingly complex disease being managed 
in the community there is a need to address the impact of 
HAI from the perspectives of acute care, community care, 
individual patient and the broader society.
Within the UK and Europe, point prevalence surveys 
have become the reference point for policy makers to 
plan infection prevention and control (IPC) strategies. 
Within Europe, each country undertakes a national 
HAI point prevalence survey every 5 years coordinated 
by the European Centre for Disease Prevention and 
Control (ECDC).5 In order to ensure that HAI preven-
tion is targeted towards infections with the highest impact 
on patient quality of life and/or the greatest reduction 
in incidence or cost, robust incidence surveillance is 
required.6 While point prevalence study design is a 
measure of disease burden and reports the proportion 
of infection types at a given point, it is a limited measure. 
Prevalence surveys use a cross-sectional approach identi-
fying active cases and as such are biased towards identi-
fying HAI of longer duration. Prevalence surveys do not 
capture risk exposure, or duration of risk exposure and 
are therefore subject to bias if used to evaluate increased 
LOS. Incidence data can be used to estimate how many 
patients will develop HAI over time, show seasonal vari-
ations, allow assessment of risk of HAI and describe the 
outcomes of HAI.
This will be the first whole hospital incidence study of 
its kind undertaken within the UK in over 20 years. The 
last similar study by Plowmanet al collected data in the 
UK in 1995.7 8 Since that time, the HAI landscape has 
changed in terms of ageing population, increasingly 
complex procedures and the emergence of antimicrobial 
resistance. A well-designed incidence survey is necessary 
to provide information on risk, aetiology and outcome of 
HAI within the current healthcare system.
objectives
The Evaluation of Cost of Nosocomial Infection (ECONI) 
survey will investigate the health impact and consequent 
costs of HAI for patients, the health service and the wider 
community. Epidemiological and health economic analyt-
ical techniques will be used. There are three broad aims 
to the study: to describe the epidemiology of HAI in terms 
of risk, time, place and person; to describe the impact of 
HAI on care in hospital, LOS, impact on health-related 
quality of life and cost from an acute care perspective and 
to describe the impact of HAI postdischarge in terms of 
health-related quality of life; health and social care util-
isation and socioeconomic impact. Each of these aims 
is broken down into research objectives with associated 
research questions (see supplementary appendix A).
MEthods And AnAlysIs
study design
ECONI is a two-centre, prospective observational inci-
dence study with record linkage, nested case-control 
and qualitative study. The case-control study component 
includes a longitudinal follow-up for 1 year postdischarge 
also encompassing a second nested study that includes 
qualitative interviews with a selected group of patients 
who acquire HAI during their hospital stay. A maximum 
variation purposive sample of patients with HAI will be 
recruited to take part in a qualitative research study during 
their hospital stay, and will be interviewed by phone after 
discharge. The aim of this sampling strategy is to ensure 
that as wide a range of perspectives from patients experi-
encing different types of HAI are included. A diagram of 
the ECONI study is shown in figure 1.
hospital setting
All Scottish acute hospitals were reviewed based on the 
number of staffed beds, annual inpatients, distribution 
of emergency, elective and transfer admissions and mean 
LOS within their hospital type.9 One large teaching 
hospital (981 beds and a 24 hours Accident and Emer-
gency (A&E) department and a number of national 
specialist services) and a large general hospital (492 beds 
with a 24 hours A&E department and a regional cardiovas-
cular centre) were selected as study sites. The study hospi-
tals represent 82% of clinical specialties served within 
Scotland and fall within the mid-range of HAI cases in 
the National HAI prevalence survey 2012.10 Teaching and 
general hospitals accounted for 91% of all admissions to 
acute care in Scotland in 2015 while the study was being 
developed.11 The two study hospitals served 100 000 
patients during 2015.11
Figure 1 Representation of the Evaluation of Cost of 
Nosocomial Infection nested study design. The incidence 
cohort represents all adult overnight admission to the study 
hospitals. The case-control study will be a subset of cases 
and controls (two controls for each case) and the nested 
qualitative study will recruit a subset of patients who develop 
healthcare-associated or nosocomial infection (HAI) and 
have consented to participate in the case-control study. A 
proportion of HAI cases will not be able or willing (including 
by proxy) to provide consent to participate in the case-control 
study.
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Case definitions
The ECONI study will use the microbiologically 
confirmed ECDC HAI epidemiological case definitions 
that are based on internationally recognised case defi-
nitions for incidence of HAI (based on the Centres for 
Disease Control (CDC) nosocomial infection definitions 
1988).12 These definitions were used within the 2012 and 
2017 European HAI Prevalence survey.13 Data on HAIs 
will be recorded on all hospital patients who meet the 
relevant case definitions. The use of these definitions will 
allow a comparison between the current HAI incidence 
study, the national prevalence survey and international 
HAI studies.
The definitions define 14 infection types which can 
affect adult patients. The timeframe for developing an 
HAI according to the ECDC case definitions13 is 48 hours 
or more after admission or day 3 of admission onwards. 
The additional onset criteria take account of cases where 
a patient is re-admitted to hospital after receiving care 
within the study hospital or another acute care facility 
(box 1). Infections originating in other acute and 
non-acute hospitals will be included but those originating 
in long-term care facilities, care homes or nursing homes 
will be excluded (these will be classified as community 
acquired).
study period
In-hospital data collection began in April 2018 and will 
continue for one calendar year. Recruitment to the nested 
case-control study will take place over the same period. 
Patients will be followed up by postal questionnaires at 
1, 3, 6 and up to 12 months after their date of discharge. 
A subset of patients will be recruited for qualitative inter-
views on their experience of HAI. Record linkage data for 
the cohort will include information on their healthcare 
during the year before the start date and 1 year after the 
final in-hospital data collection date.
Incidence cohort survey
The incidence survey is an observational epidemiological 
surveillance study. The incident or outcome event for 
the incidence survey is HAI as defined by the ECDC case 
definitions. ECONI study nurses will work closely with 
local infection control teams; they will have full access 
to local patient management systems, infection control 
systems (IC Net) and laboratory data. ECONI nurses 
will identify patients with one or more suspected HAI 
through searching laboratory systems for positive labo-
ratory reports, consultation with infection control teams 
and ward staff. Case note review will be undertaken to 
assess whether these suspected cases meet the ECDC case 
definitions.
Inclusion criteria
 ► Age 18 years or over.
 ► Admitted to hospital for an overnight stay at study 
hospitals.
 ► Any sex.
 ► HAI diagnosed using ECDC case definitions and time 
scales
Exclusion criteria
 ► Age under 18 years.
 ► Admitted as a day case to a study hospital.
 ► Patient does not acquire HAI according to ECDC case 
definitions and time scales.
routine data sets
The Community Health Index (CHI) number is a unique 
identifier allocated to every patient and can be used 
to link to routine data sets collected by NHS Scotland. 
CHI will be collected for all patients with HAI and this 
will enable analysis to separate patient-level data for 
cases and non-cases in the admission cohort. Linkage 
to routine data sets will be used to collect information 
for all patients within the admission cohort. These data-
bases include the Scottish Morbidity Register ‘SMR01’: 
a record of all hospital admissions and discharges to 
acute hospitals. The SMR01 data set links to the Scottish 
death register which records the date of death and the 
cause of death as described by the International Classi-
fication of Disease version 10 (ICD-10)14 and operations 
are recorded using OPCS-415 classification. The ‘SMR00’ 
database records information on attendance at outpa-
tient clinics for treatment or investigation. Linkage will 
also be made to the data sets which record patient-level 
community prescribing in Scotland (the ‘Prescribing 
Information System for Scotland') and the Community 
Health Activity Data—District Nursing data set which is 
a relatively new data set (dates from 2015) that records 
information on community nursing visits to patients. 
Both SMR00 and SMR01 data sets are estimated to be 
97% complete.16 It is acknowledged that newer data sets 
box 1 the criteria that are required to meet the European 
Centre for disease Prevention and Control case definitions 
of healthcare-associated or nosocomial infection (hAI). hAI 
must meet both criteria a and b.
a. HAI is an infection that met the HAI case definitions during the pa-
tient's stay.
b. In addition, the onset of infection must have occurred within one of 
the following time frames:
i. The infection occurred on day 3 of current admission onwards (if 
day 1 is day of admission).
ii. Present on admission (or presenting on day 1 or 2) in patients 
discharged from hospital in previous two days.
iii. Surgical site present on admission (or presenting day 1 or 2) if 
surgery within 30 days of signs and symptoms appearing if no 
implant and within 90 days of signs and symptoms appearing if 
an implant was present.
iv. Clostridium difficile infection present on admission (or present-
ing day 1 or 2) in patients discharged from hospital in previous 
28 days.
v. Device associated infection (pneumonia, urinary tract infection, 
bloodstream infection and catheter-related infection following 
the insertion of the device (including day 1 or 2 of admission).
 o
n
 23 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026687 on 19 June 2019. Downloaded from 
4 Stewart S, et al. BMJ Open 2019;9:e026687. doi:10.1136/bmjopen-2018-026687
Open access 
will have lower completion rates and this will be consid-
ered in the analysis.
Case-control study
For the nested case-control study an incidence density 
sampling approach will be used. The protocol aims to 
recruit all eligible patients with HAI and two patients 
without HAI at time of recruitment. Cases will have been 
identified within the incidence survey.
Inclusion criteria
 ► Admitted to hospital for an overnight stay at study 
hospital.
 ► Subjects capable of giving informed consent, or if 
appropriate, subjects having an acceptable individual 
capable of giving consent on the subject’s behalf.
 ► Any sex.
 ► Age 18 years and over.
 ► Good English language skills (sufficient to read and 
understand the participant information sheet without 
help).
Exclusion criteria
 ► Admitted to hospital as a day case.
 ► Admitted to hospitals other than the study hospitals.
 ► Age under 18 years.
 ► Admitted to the study hospital during the study period 
and recruited to the study during a previous stay.
 ► Subjects not capable of giving informed consent 
unless legal representative or relative can provide 
proxy consent.
 ► Patients who do not have sufficient English language 
skills to read and understand the information sheet 
without help.
 ► Patients cared for under the hospital at home care 
pathway.
 ► Admitted to hospital as a day case.
Controls will be selected at random from the cohort of 
patients without HAI who are being cared for on the same 
ward as the cases. Controls will be selected using a random 
number generator from the same ward as the case at the 
same time period. The ECONI nurses will approach the 
clinical teams to ensure that patients meet the inclusion 
criteria, and if being recruited as a case, they must be 
aware of their infection and considered well enough to be 
invited to take part. The initial approach to the patient will 
be by the clinical team caring for the patient. Patients will 
be asked to provide consent after reviewing the patient 
information sheet provided. ECONI nurses will seek a 
guardian, welfare attorney or family member to provide 
consent for patients who are unable to consent for them-
selves. This approach will ensure that the case-control 
study includes the most unwell and patients potentially 
at risk of HAI.
Patients or their proxies who have provided informed 
consent will be sent a short paper questionnaire at 1, 3, 6 
and 12 months after discharge from the episode of care 
when they were recruited. They will be provided with a 
prepaid return envelope. The National Death Registry 
will be contacted in order to identify any patients who 
have died since discharge; this will ensure that their fami-
lies will not be contacted after their relatives have died. 
The ECONI nurses will also undertake a case note review 
collecting clinical data which is not routinely available.
A flow chart showing the patient pathway and data 
collection/recruitment points is shown in figure 2. 
ECONI nurses will be trained to collect data using a 
bespoke data collection tools for each study design using 
REDCap software.17
Variables
Table 1 shows the outcomes of interest for the ECONI 
study.
data sources/measurement
Table 2 shows the variables which will be recorded for the 
study and the sources of these data. Extrinsic risk factors 
which are patient care practices inclusive of devices, 
surgeries and isolation will be included in the analysis. 
Known confounding intrinsic patient characteristics will 
also be included within the analyses. These include: sex, 
age, ethnicity, socioeconomic status as defined by Scottish 
Figure 2 Evaluation of Cost of Nosocomial Infection 
study flow chart. HAI, Healthcare Associated Infection or 
Nosocomial Infection.
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Index of Multiple Deprivation and comorbidities from 
the SMR01 data set using ICD-10 definitions.18 For the 
case-control study, factors like underlying comorbid-
ities, health status measured by McCabe score, age and 
complexity of surgeries will be considered within the anal-
ysis as potential confounders in terms of increased LOS.
data linkage
Data from the incidence survey, routine data sets and 
case-control study will be combined to form an ECONI 
data set (figure 3).
Qualitative interview
A subgroup of patients who have been identified as having 
HAI will be invited to take part in a qualitative interview 
between 1 and 3 months after they have been discharged 
from hospital. This will investigate the experiences of 
patients who have had an HAI; the effect this infection 
has had on their life since discharge from hospital, how 
they have coped with having this infection and how this 
experience could have been improved.
Inclusion criteria
 ► Patients who consented to be contacted for follow-up 
interview.
 ► Patients who acquired HAI.
 ► Patients who are able to consent for themselves (this 
will be checked to ensure that they remember the 
study and are still willing and physically able to take 
part).
 ► Good English language skills (sufficient to read and 
understand the participant information sheet).
 ► Willing and able informant.
Exclusion criteria
 ► Patients who did not consent to follow-up.
 ► Patients who did not acquire HAI.
 ► Patients who are not able to consent for themselves.
 ► Patients who do not have English language skills.
 ► Patients who are not willing to participate in a tele-
phone interview.
study size
The ECONI study is an observational study. The two study 
hospitals admitted 100 000 patients during 2015 when the 
study was planned. A hospital HAI incidence of about 
0.5%–1% per admission is anticipated, yielding around 
500–1000 incident HAI cases from an admission cohort 
of 100 000 admissions over the period of 1 year. Individ-
uals may have multiple HAIs during their stay in hospital 
so the power for this part of the study is evaluated for 
the comparison of Poisson rates.19 For a rare exposure 
factor in 5% of patients, risk ratios in the exposed group 
in excess of 1.47 will be detected with a power in excess 
of 90% when around 700 HAI cases are anticipated. If 
the anticipated number of HAI cases is lower at around 
500 then the detectable risk ratio is 1.55 and if it is higher 
at around 1000 HAI cases then the detectable risk ratio 
is 1.4, both at a power of 90%. If the risk factor is more 
prevalent at 30% then for powers in excess of 90%, the 
detectable risk ratios are >1.28 for around 500 anticipated 
HAI cases, 1.24 for around 700 anticipated HAI cases and 
1.2 for around 1000 anticipated HAI cases. This demon-
strates that the study is expected to be large enough to 
detach moderate risk ratios associated with the acquisi-
tion of an HAI.
statistical analysis
Baseline characteristics will be summarised for the whole 
admission cohort; for patients who develop HAI and 
those who do not. Missing data will be reported for each 
variable. The analysis of the rate of acquisition of HAI in 
hospital will be carried out using time to event models, 
such as Poisson regression, Cox or parametric survival 
models. This will be reported as the rate per 1000 patient 
days, or per 1000 admissions, together with 95% CIs. For 
each patient, time will begin on admission to hospital 
and will end with discharge, death or acquisition of an 
HAI. Multiple admissions from the same patients will 
be modelled using a frailty component or adjusting the 
SEs of the estimated effect to account for the multiple 
Table 1 ECONI outcomes for incidence survey and case-
control study
Incidence survey
Epidemiological 
outcomes Data items
Infection Type of infection ECDC case definitions13
Causative organism
Antimicrobial resistance of causative organism
Duration of 
infection
Start date of infection
End date of infection
Morbidity Attributable additional bed days required as a 
result of infection
Mortality 30-Day mortality
Case-control study
Socioeconomic outcomes Data items
Cost of illness from hospital 
perspective
Attributable additional bed days 
required as a result of infection
Cash treatment costs (including tests, 
treatment, IPC measures, equipment)
Cost of illness from acute 
care perspective
Attributable additional visits to 
outpatient clinic
Re-admission to hospital
Cost of illness from a primary 
care perspective
GP prescribing
District nurse visits
Cost of illness from patient's 
perspective
Quality of life (EQ-5D,28 SF-1229)
Lost income
Cost of illness from patient’s 
family perspective
Caring responsibilities to be covered
Additional care requirements to be 
provided by family
Cost of illness from a societal 
perspective
Days of work lost
Bed days used
Social care provided
ECDC, European Centre for Disease Prevention and Control; 
ECONI, Evaluation of Cost of Nosocomial Infection; EQ-5D, 
EuroQol-5D; GP, general practitioner; IPC, infection prevention and 
control; SF-12, 12-Item Short Form Health Survey. 
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Table 2 ECONI data items for incidence survey and case-control study and sources of data
Concept Data items Data sources
Incidence survey—data collected by ECONI nurses
  HAI infection type Infection type13
Causative organism13
Antibiotic resistance30
Date infection identified
Patient clinical records, laboratory systems, 
nursing notes including GP letters
Record linkage—linked using CHI number
  Age Date of birth SMR0131
  Patient health International Statistical Classification of Diseases and 
Related Health Problems14 32 from SMR01
  Socioeconomic status Scottish Index of Multiple Deprivation18
  Ethnicity Ethnicity as defined by census
  Hospital admissions post discharge Date of hospital admission
Date of discharge
  Outpatient clinic attendance Date and number of outpatient clinic visits SMR0019
  GP prescribing of antibiotics Antimicrobial agents prescribed
Dosage
Frequency of dosage
No. of days
Prescribing Information System for 
Scotland33
  District nurse visits Number of district nurse visits Community Health Activity Data—District 
Nursing34
  Deaths Date of death
Cause of death
National records of Scotland death 
records35
Case-control study—recorded by ECONI nurses
  Lifestyle Smoking
Drinking
  Severity of illness McCabe score36
Continence
Clinical case note review
  Screening MRSA screening
CPE screening
  Antimicrobial use Type of antimicrobial agent13
Route of administration
Dose
Frequency
No. of days
Indication for prescribing
Drug Kardex
  Surgery Surgery type
Office of Population Censuses and Surveys 
Classification of Surgical Operations and Procedures 
(fourth revision)15 Wound classification
American Society of Anaesthesiologists score37
Date of operation
Duration of surgery
Patient weight/height
Surgical note review
  Device use Type of device present
PVC,
Urinary catheter CVC I have 
Date inserted
Date removed
Clinical case note review
  Complications in hospital Adverse events
Case-control studies—patient questionnaires
Continued
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observations per patient. This analysis can also deal with 
multiple HAI events during the one admission episode. 
The impact of HAI on mortality or LOS will also be esti-
mated using Cox or parametric survival models. Time 
will begin on admission to hospital and the occurrence 
of an HAI will be a time-dependent variable. Patients will 
initially be in the no HAI group on admission to hospital 
and some will then move into the HAI group during their 
hospital stay.
The nested case-control study, where additional data are 
collected on HAI cases and two controls, will be analysed 
using matched logistic regression to estimate the impact 
of risk factors on HAI. Time to event models will be used 
to estimate the impact of HAI on mortality and additional 
LOS. In this analysis, time will begin on the date when 
the case receives the initial HAI diagnosis. The matched 
controls will also use this date. Comparing LOS for the 
cases and matched controls will provide the additional 
LOS associated with HAI. Analysis will be undertaken 
using R statistical software.20
health economic analysis
This study will estimate the cost of HAI by HAI type to 
acute healthcare, to community care, social care services 
and costs to patients. This study will report an estimated 
of cost of HAI in Scotland and the UK using a number 
of approaches including accounting costs, cash treatment 
costs and willingness to pay.
EuroQol-5D (EQ-5D) and 12-Item Short Form Health 
Survey (SF-12) questions will be completed by all 
consented patients or proxies. The wording of the proxy 
questionnaires to be completed by the guardians, welfare 
attorneys or family members has been adjusted so as 
to reflect the perspective of the person completing the 
questionnaire. This includes use of the proxy version of 
EQ-5D. Utility values will be calculated from the EQ-5D 
and from the Short-Form Six-Dimension (derived from 
the SF-12).21 These utility values are required in the calcu-
lation of quality-adjusted life-years, which is a multidimen-
sional measure of health outcome incorporating quality 
of life and length of life. Existing studies on the impact 
of HAI on patients’ quality of life are limited to a specific 
organisms (Clostridium difficile22 23) or hospital settings.24
Costs will be calculated from a range of perspec-
tives including acute hospital care, primary care and 
the patient’s perspective. Cost within acute care will 
be primarily based on additional attributable LOS 
using multistate modelling. The costs of each infection 
Concept Data items Data sources
  Quality of life EQ-5D28
SF-1229
Patient self-report by questionnaire or 
completed by proxy. A proxy version of the 
questionnaire has been prepared.  Living arrangements Current residence
Marital status
  Education Education
  Work Current employment
Work days lost
Salary
  Caring Care provided
Care received
  Healthcare utilisation Use of healthcare services not available through record 
linkage
  Date questionnaire completed 
CHI, Community Health Index; CPE, Carbapenemase Producing Enterobacteriacae; CVC, Central venous catheter; ECONI, Evaluation of Cost 
of Nosocomial Infection; EQ-5D, EuroQol-5D; GP, general practitioner; HAI, healthcare-associated or nosocomial infection; IPC, infection 
prevention and control; MRSA, Meticillin Resistant Staphylococcus aureus; PVC, Peripheral venous catheter; SF-12, 12-Item Short Form 
Health Survey. 
Table 2 Continued 
Figure 3 ECONI data linkage. Data sets which will 
be combined in order to address the study research 
questions. ECONI, Evaluation of Cost of Nosocomial 
Infection; ISD, Information Services Division.  
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will be calculated using the cost of the laboratory tests 
required to identify the infection including follow-up 
tests; infection prevention and control measures imple-
mented according to infection type and resistance of the 
organism and specific treatment costs for the infection. 
Indirect costs to patients including forgone earnings due 
to changes in employment circumstances and impact on 
personal care requirements will also be reported.
strengths and limitations of this study
Whole hospital incidence is rarely available. The study 
will also report causative organisms and antibiotic suscep-
tibilities for all HAI incident infections which is currently 
unknown. Data collection will take place over one 
calendar year to ensure that infections that show seasonal 
variation will be included within the data set. However, 
the single year of data collection will not be sufficient to 
identify seasonal trends which would require multiple 
annual surveys. The study will link high-quality health data 
for recruited patients, in order to evaluate risk factors, 
healthcare utilisation and mortality, which will mitigate 
absent data from patients who are lost to follow-up. Post-
discharge information on detailed follow-up for socioeco-
nomic outcome is rarely available; this will be achieved 
by following up patients after discharge with question-
naires. The study will report quality of life scoring using 
the EQ-5D and SF-12 instruments for up to 1 year after 
patients have been discharged from hospital. This is novel 
since there are no HAI-specific instruments available as 
yet and if they do exist are disease or setting specific.22–24 
Similarities and differences for HAI patients between the 
instruments are not available in the literature. Previous 
studies have a narrow definition of cost focusing only on 
historical accounting costs that may not be representa-
tive of economic costs. HAI’s burden in a public health 
system such as the National Health Service (NHS) can 
be better described in terms of wasted resources. ECONI 
will produce a unique detailed set of HAI costs infor-
mation that can be used in the economic evaluation of 
IPC programmes. Finally, the inclusion of a qualitative 
interview will collect personal accounts of the experience 
of developing HAI which will provide a patient-centred 
perspective to the study.
A limitation of the case-control study is the fact that 
the patients at greatest risk of HAI constitute the most 
elderly and unwell and these patients may not have the 
capacity to consent for themselves. This limitation is miti-
gated by the option to ask a guardian, welfare attorney 
or family member, who can make decisions about the 
study on the patient’s behalf. If patients are temporarily 
unable to provide consent but recover capacity before 
they are discharged, then they will be asked to provide 
their consent to take part in the remainder of the 
study, should they wish to do so. Patients may be lost to 
follow-up during the postdischarge phase and this would 
impact on patient-reported outcomes. Such a limitation 
has been largely mitigated by the fact that information on 
mortality, repeat hospitalisations, community prescribing 
and use of district nursing teams will be available for all 
patients.
Potential for bias
Selection bias will be addressed because all newly admitted 
patients will be included within the admission cohort and 
the outcome will not be known at the time of admission 
(unless patients are readmitted with active HAI). Patients 
will be observed during their hospital stay, they will be 
monitored using patient management systems (including 
laboratory databases) so the loss to follow-up for the 
incidence study will be minimal. Chronology bias will be 
reduced as all patients (with and without HAI) will be 
admitted over same 1-year period. Data will be collected 
over one calendar year in order to account for variations 
in case mix and causative organisms throughout the 
seasons. Interobserver bias is addressed through inter-
rater reliability tests being undertaken before and during 
the study to ensure that their application of the case defi-
nitions are consistent and validation of diagnosed cases 
undertaken by the study manager on a fortnightly basis.
Patients who do not have sufficient English language 
skills to read and understand the patient information 
sheet will be excluded from the case-control study. There 
is potential for bias from this because patients who have 
lived abroad may be at increased risk of antibiotic-resis-
tant infections. These patients will be included within the 
incidence cohort and the infection type, and causative 
organism and antibiotic susceptibilities will be recorded 
as part of the surveillance part of the study.
Using record linkage means that key events do not 
rely on patient recall. For the postdischarge phase of the 
case-control study it is anticipated that patients will be lost 
to follow-up. These patients will be well described from 
the incidence study and the demographics of any lost 
patients can be clearly reported. Response bias for cases 
and controls will be assessed by comparing the character-
istics of the cases and controls with the admission charac-
teristics of all admissions during the study period.
Governance summary
The study reports to the ECONI Steering Committee who 
provided overall supervision of the trial. The committee 
contains members independent of the investigators and 
their employers and includes two members of the public.
Patient and public involvement
Two members of the public were recruited to the steering 
committee to represent the patients' and their families’ 
perspective. These public representatives reviewed the 
research questions, patient facing information and ques-
tionnaires. A recent review of the literature on patient 
experience of HAI identified 17 studies which had inves-
tigated the impact of HAI on patients.25 The findings of 
this paper will be used to inform the qualitative interview 
questions. Patients have not been involved in recruitment 
and conduct of the study due to the rapidly changing 
hospital population. The public representatives will work 
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with researchers to prepare a lay summary of each of the 
publications from the study, which will be available from 
the ECONI study website. Patients will be sent a summary 
of the findings of the study in a final communication 
which will thank them for their participation.
Ethics and dissemination
The incidence study is led by NHS Health Protection 
Scotland and was deemed ineligible for ethical review 
as it was a public health surveillance study.26 The inci-
dence survey and record linkage protocol was approved 
on 1 February 2017 by the NHS Scotland Public Benefit 
and Privacy Panel for Health and Social Care (PBPP) 
(reference 1617–0037). The PBPP is the governance 
structure of NHS Scotland and they exercise delegated 
decision-making on behalf of NHS Scotland Chief Exec-
utive Officers and the Registrar General. The panel oper-
ates as a centre of excellence for privacy, confidentiality 
and information governance expertise in relation to 
Health and Social Care in Scotland.
The main ethical issues with the study are the balance 
between the patients’ frailty and the need to collect data 
from the patients' perspective. The research nurses will 
discuss potential recruitment of patients with the nurses 
caring of them to ensure that the patients are aware of 
their infection (for cases) and that they are well enough 
to discuss consent before they are approached. In order to 
avoid any unnecessary distress to family members, a check 
will be undertaken with the national death registry before 
questionnaires are posted to patients. The protocol will 
seek consent from a proxy (the patient’s legal representa-
tive, guardian, welfare attorney or nearest relative) autho-
rised to take decisions regarding research. This phase 
of the study was approved by PBPP on the 25 May 2017 
(reference 1617–0329).
All publications arising from the ECONI study will be 
published in open-access peer-reviewed journals. Lay 
summaries will be made available to participants. The 
study will follow the NHS Information Services Division 
protocol for statistical disclosure27 in order to ensure 
patient confidentiality is maintained. An anonymised data 
set will be produced at the end of the study and these data 
will be available for future studies. This will be subject to 
agreement with the Chief Investigator JR.
ConClusIons
ECONI will be a multisite study on the current incidence 
and impact of HAI in Scotland. This will include the 
incidence of causative organisms and AMR data. These 
incidence rates will be extrapolated based on specialty 
of treatment to generate estimates of Scotland and UK 
wide HAI. It will provide detailed epidemiological infor-
mation on the occurrence of HAI and identify patients 
who are at increased risk of developing HAI. The study 
will report previously unreported health utility values for 
a range of HAIs, which can be used to inform modelling 
and decision making on HAI prevention and control 
interventions.
International implications
While this study will benefit NHS Scotland, the findings 
will elicit health state utility values for HAI types which 
can be used in the economic evaluation of IPC interven-
tions elsewhere. The epidemiology of HAI in Scotland 
in terms of causative organisms and antibiotic resistance 
patterns are comparable to countries within northern 
Europe at this time. Data collected during the ECONI 
study will allow comparison with the findings of the 2016 
European HAI prevalence survey. The use of electronic 
health data will allow validation of the representative-
ness of the recruited patients and the generalisability at a 
national and international level.
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